Neuromidin, 5 mg/ml, solution for intramuscular and subcutaneous administration, 1 ml, 10 pcs.
Approved by the Pharmacological Committee of the Russian Ministry of Health
INSTRUCTIONS (information for the patient) for the use of the drug NEIROMIDINUM
International nonproprietary name
Ipidacrine (9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline hydrochloride monohydrate).
Dosage form
Pills.
Compound
Ipidacrine 20 mg.
Excipients: lactose, potato starch, calcium stearate.
Description
White tablets. In appearance they must comply with the requirements of the Global Fund XI, issue 2, p. 154.
Diameter - 6.0±0.2 mm.
Height - 2.7±0.3 mm.
Pharmacotherapeutic group
Cholinesterase inhibitor, neuromuscular conduction stimulator/ATS - N07AAOO.
Pharmacological properties
Neuromidin is a reversible cholinesterase inhibitor and also has a direct stimulating effect on impulse conduction at the neuromuscular synapse and in the central nervous system due to blockade of potassium channels in the excitable membrane.
Neuromidin enhances the effect on smooth muscles of not only acetylcholine, but also adrenaline, serotonin, histamine and oxytocin.
Neuromidin has the following pharmacological effects:
— restores and stimulates neuromuscular transmission;
- restores the conduction of impulses in the peripheral nervous system, disturbed due to the influence of various factors (trauma, inflammation, exposure to local anesthetics, some antibiotics, potassium chloride and other factors);
- enhances the contractility of smooth muscle organs under the influence of all agonists, with the exception of potassium chloride;
- moderately stimulates the central nervous system;
- improves memory and learning.
The drug does not have teratogenic, embryotoxic, mutagenic and carcinogenic, as well as allergenic or immunotoxic effects. The drug does not have a negative effect on the endocrine system.
After oral administration, Neuromidin is rapidly absorbed. The maximum concentration in the blood is observed after one hour. From the blood, Neuromidin quickly enters the tissues, and in the stabilization stage only 2% of the drug is found in the blood serum. Elimination of Neuromidin occurs through the kidneys, as well as extrarenally (biotransformation, secretion in bile). Only 3.7% of Neuromidin is excreted unchanged. This indicates the rapid metabolism of Neuromidin in the body.
Indications for use
Neuromidin is used in adults for diseases of the peripheral nervous system (neuritis, polyneuritis and polyneuropathy, polyradiculoneuropathies, myasthenia gravis and various myasthenic syndromes); bulbar paralysis and paresis, in the recovery period with organic lesions of the central nervous system, accompanied by motor disorders; in complex therapy of demyelinating diseases, with intestinal atony.
Contraindications
The use of Neuromidin is contraindicated in cases of epilepsy, extrapyramidal diseases, angina pectoris, severe bradycardia, bronchial asthma, individual hypersensitivity to the drug, vestibular disorders, peptic ulcer in the acute stage.
Use of the drug during pregnancy and lactation
Neuromidin penetrates well into all tissues of the body, increases the tone of the uterus and can cause premature birth, so it is not recommended to use the drug during pregnancy. The drug is used for weak labor. Contraindicated during breastfeeding.
Directions for use and doses
Neuromidin is used orally 1-3 times a day. A single dose of the drug is 10–20 mg (0.01–0.02 g) (0.5–1 tablets). For lesions of the peripheral nervous system, myasthenia gravis and myasthenic syndromes, the drug is prescribed orally at 10–20 mg (0.01–0.02 g) 1–3 times a day for 1–2 months. For short-term courses of treatment of patients with severe disorders of neuromuscular transmission, a single dose can be 20–40 mg (0.02–0.04 g) orally (1–2 tablets) 5–6 times a day.
For the treatment and prevention of intestinal atony, 20 mg (0.02 g) is prescribed 2-3 times a day for 1-2 weeks. If the next dose has not been taken, then continue the course of treatment at the previously prescribed doses. If necessary, you should consult your doctor.
special instructions
The drug increases the muscle tone of the uterus and can cause premature labor. Prescribe with caution for gastric ulcers, thyrotoxicosis, and diseases of the cardiovascular system.
Neuromidin penetrates well into tissues and organs, including the brain, and can have a sedative effect. Therefore, persons using Neuromidin should be careful when working with machinery. During treatment you should not drink alcohol.
Drug interactions
The drug enhances the sedative effect when interacting with central nervous system depressants. The action and side effects are enhanced when used together with other cholinesterase inhibitors and m-cholinomimetic drugs. In patients with myasthenia gravis, the risk of cholinergic crisis increases if Neuromidin is used simultaneously with other cholinergic drugs. Beta-blockers cause bradycardia if they were used before treatment with Neuromidin. When used simultaneously with alcohol, adverse side effects may increase.
Overdose
In case of Neuromidin poisoning or its relative overdose, m-anticholinergic blockers are used: atropine, cyclodol, etc.
Side effects
When using Neuromidin, hypersalivation, bradycardia, dizziness, nausea, vomiting, and allergic skin reactions (itching, rash) are possible. In these cases, reduce the dose or discontinue the drug. Hypersalivation and bradycardia can be reduced with m-anticholinergic blockers.
If during treatment with Neuromidin side effects are discovered that are not listed in the instructions, then it is necessary to inform the attending physician.
Manufacturer
JSC Olainsky Chemical-Pharmaceutical.
Address: st. Rupnicu 5, Olaine, LV-2114, Latvia.
Buy Neuromidin solution intravenously and intramuscularly 15 mg/ml 1 ml No. 10 in pharmacies
Instructions for use Neuromidin solution IV and IM 15 mg/ml 1 ml No. 10
Dosage forms injection solution 15 mg/ml 1 ml Synonyms Axamon Ipigrix Group Cholinesterase inhibitors International nonproprietary name Ipidacrine Composition Active substance: Ipidacrine. Manufacturers: Olainfarm JSC (Latvia), Olainfarm JSC, packaged Sopharma JSC (Latvia), Olainfarm Olainsky HFZ (Latvia) Pharmacological action Reversibly inhibits cholinesterase, stimulates impulse conduction in neuromuscular synapses and in the central nervous system due to blockade of potassium channels of the excitable membrane. Restores and stimulates neuromuscular transmission (including in the peripheral nervous system), enhances the contractility of smooth muscle organs, moderately stimulates the central nervous system, improves memory and learning. Does not have teratogenic, embryotoxic, mutagenic, carcinogenic, allergenic, or immunotoxic effects. Does not affect the endocrine system. The drug penetrates well into all tissues of the body, increases the tone of the uterus and can cause premature birth. The drug can be used for weak labor. After oral administration, it is quickly absorbed. It is excreted through the kidneys and through the gastrointestinal tract, mainly in the form of metabolites. Side effects: Dizziness, bradycardia (can be eliminated with m-anticholinergic blockers), hypersalivation (can be eliminated with m-anticholinergic blockers), nausea, vomiting, itching, rash. Indications for use Diseases of the peripheral nervous system in adults (neuritis, polyneuritis, polyneuropathy, polyradiculoneuropathy, myasthenia gravis); bulbar palsy and paresis, organic lesions of the central nervous system, accompanied by nervous disorders (recovery period); demyelinating diseases (complex therapy), intestinal atony. Contraindications Hypersensitivity, epilepsy, extrapyramidal disorders, severe bradycardia, angina pectoris, bronchial asthma, vestibular disorders, gastric ulcer in the acute stage, pregnancy, breastfeeding. Overdose Treatment: prescription of m-anticholinergics, incl. atropine, cyclodol, etc. Interaction Strengthens the sedative effect of central nervous system depressants. M-cholinomimetics and other cholinesterase inhibitors increase the effect and side effects (the risk of a cholinergic crisis increases, especially in patients with myasthenia gravis). Beta-blockers cause bradycardia if they were used before treatment with Neuromidin. When used simultaneously with alcohol, adverse side effects may increase. Special instructions The drug increases the muscle tone of the uterus and can cause premature labor. Caution should be used for stomach ulcers, thyrotoxicosis, and diseases of the cardiovascular system. The drug penetrates well into tissues and organs, incl. brain and may have a sedative effect. Care should be taken when working with machinery. During treatment you should not drink alcohol. Storage conditions List A. In a place protected from light, at a temperature not exceeding 25 °C.
Buy Neuromidin solution intravenously and intramuscularly 5mg/ml 1ml No. 10 in pharmacies
Instructions for use
Neuromidin solution IV and IM 5 mg/ml 1 ml No. 10
Dosage forms injection solution 5 mg/ml 1 ml Synonyms Axamon Ipigrix Group Cholinesterase inhibitors International nonproprietary name Ipidacrine Composition Active substance: Ipidacrine. Manufacturers: Olainfarm JSC (Latvia), Olainfarm JSC, packaged Sopharma JSC (Latvia), Olainfarm Olainsky HFZ (Latvia) Pharmacological action Reversibly inhibits cholinesterase, stimulates impulse conduction in neuromuscular synapses and in the central nervous system due to blockade of potassium channels of the excitable membrane. Restores and stimulates neuromuscular transmission (including in the peripheral nervous system), enhances the contractility of smooth muscle organs, moderately stimulates the central nervous system, improves memory and learning. Does not have teratogenic, embryotoxic, mutagenic, carcinogenic, allergenic, or immunotoxic effects. Does not affect the endocrine system. The drug penetrates well into all tissues of the body, increases the tone of the uterus and can cause premature birth. The drug can be used for weak labor. After oral administration, it is quickly absorbed. It is excreted through the kidneys and through the gastrointestinal tract, mainly in the form of metabolites. Side effects: Dizziness, bradycardia (can be eliminated with m-anticholinergic blockers), hypersalivation (can be eliminated with m-anticholinergic blockers), nausea, vomiting, itching, rash. Indications for use Diseases of the peripheral nervous system in adults (neuritis, polyneuritis, polyneuropathy, polyradiculoneuropathy, myasthenia gravis); bulbar palsy and paresis, organic lesions of the central nervous system, accompanied by nervous disorders (recovery period); demyelinating diseases (complex therapy), intestinal atony. Contraindications Hypersensitivity, epilepsy, extrapyramidal disorders, severe bradycardia, angina pectoris, bronchial asthma, vestibular disorders, gastric ulcer in the acute stage, pregnancy, breastfeeding. Overdose Treatment: prescription of m-anticholinergics, incl. atropine, cyclodol, etc. Interaction Strengthens the sedative effect of central nervous system depressants. M-cholinomimetics and other cholinesterase inhibitors increase the effect and side effects (the risk of a cholinergic crisis increases, especially in patients with myasthenia gravis). Beta-blockers cause bradycardia if they were used before treatment with Neuromidin. When used simultaneously with alcohol, adverse side effects may increase. Special instructions The drug increases the muscle tone of the uterus and can cause premature labor. Caution should be used for stomach ulcers, thyrotoxicosis, and diseases of the cardiovascular system. The drug penetrates well into tissues and organs, incl. brain and may have a sedative effect. Care should be taken when working with machinery. During treatment you should not drink alcohol. Storage conditions List A. In a place protected from light, at a temperature not exceeding 25 °C.
